The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis
1 other identifier
observational
150
1 country
1
Brief Summary
Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and the control group, there are differentially expressed molecules in PACG patients with zonular laxity, and a potential mechanistic network can be constructed therefrom.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2025
CompletedFirst Submitted
Initial submission to the registry
March 20, 2026
CompletedFirst Posted
Study publicly available on registry
April 20, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2027
April 20, 2026
April 1, 2026
2 years
March 20, 2026
April 13, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Concentration of differentially expressed molecules in PACG patients with zonular laxity
Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and healthy control subjects, differentially expressed molecules will be identified and quantified by high-throughput omics sequencing and bioinformatics analysis in PACG patients with zonular laxity, and a potential mechanistic network will be constructed based on these molecular changes.
2 years
Study Arms (3)
Case Group A
PACG patients with zonular laxity
Case Group B
PACG patients without zonular laxity
Control Group
cataract patients without a history or signs of glaucoma
Interventions
No Additional Experimental Intervention
Eligibility Criteria
PACG patients with or without zonular laxity, as well as age-related cataract patients without a history or signs of glaucoma who served as the control group.
You may qualify if:
- Clinically diagnosed with primary angle-closure glaucoma (PACG)
- Aged ≥ 50 years, no gender restriction
- Case Group A: Undergoing glaucoma surgery with intraoperatively confirmed significant zonular laxity
- Case Group B: Undergoing glaucoma surgery with intraoperatively confirmed normal zonular morphology
- Control group: age- and sex-matched with case groups; clinically diagnosed with age-related cataract; normal anterior chamber depth and angle; no history or signs of glaucoma; undergoing cataract surgery
You may not qualify if:
- Secondary glaucoma
- History of previous intraocular surgery
- Systemic diseases that can cause abnormal ocular zonules
- Other severe ocular diseases
- Long-term use of medications affecting connective tissue metabolism
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430000, China
Biospecimen
aqueous humor,anterior lens capsule,peripheral blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Wen Zeng, doctor
Zhongnan Hospital
- STUDY DIRECTOR
Nan Zhang, doctor
Zhongnan Hospital
- PRINCIPAL INVESTIGATOR
Xuetian Yu, student
The Second Clinical College of Wuhan University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 20, 2026
First Posted
April 20, 2026
Study Start
October 1, 2025
Primary Completion (Estimated)
September 30, 2027
Study Completion (Estimated)
September 30, 2027
Last Updated
April 20, 2026
Record last verified: 2026-04